ZCCHC10

ZCCHC10 functions as a tumor suppressor that stabilizes p53 by directly binding p53 and competitively disrupting the p53–MDM2 interaction, thereby attenuating MDM2-mediated ubiquitination and degradation of p53; this mechanism is required for ZCCHC10's anti-proliferative, anti-invasive, and chemosensitizing activities in wild-type p53-expressing cancer cells (PMID:31138778). ZCCHC10 also partners with the transcription factor PITX1 via its homeodomain to cooperatively repress hTERT transcription (PMID:31404068), and suppresses NF-κB signaling to inhibit epithelial–mesenchymal transition and invasion (PMID:33517196). ZCCHC10 expression is epigenetically silenced in cancer through lncRNA SNHG1-directed recruitment of DNMT1 and DNMT3B to its promoter CpG island, leading to promoter hypermethylation and loss of p53 stabilization (PMID:37052262).

1. 2019 High

   Establishing ZCCHC10 as a p53 stabilizer resolved how this previously uncharacterized zinc-finger protein suppresses tumor growth: it directly binds p53, disrupts the p53–MDM2 interaction, and blocks MDM2-mediated ubiquitination and degradation of p53, making its tumor-suppressive effects strictly dependent on wild-type p53.

   Evidence Reciprocal co-IP, epistasis with p53 inhibitor pifithrin-α and activator Nutlin-3, in vitro and xenograft lung cancer models

   PMID:31138778

   Open questions at the time

   • Structural basis for the ZCCHC10–p53 interaction and the precise binding interface on MDM2 are unknown
   • Whether ZCCHC10 affects MDMX-mediated p53 regulation has not been tested
   • Endogenous stoichiometry of the ZCCHC10–p53–MDM2 competitive mechanism has not been quantified
2. 2019 Medium

   Identification of ZCCHC10 as a PITX1 cofactor that cooperatively represses hTERT transcription revealed a second tumor-suppressive axis independent of p53 stabilization.

   Evidence FLAG pull-down, homeodomain-deletion mutagenesis, luciferase reporter assays in melanoma cells

   PMID:31404068

   Open questions at the time

   • The ZCCHC10–PITX1 interaction has been shown only by pull-down in a single study without reciprocal co-IP
   • Whether ZCCHC10–PITX1-mediated hTERT repression is functionally relevant in vivo remains untested
   • The domain in ZCCHC10 required for PITX1 binding is not mapped
3. 2021 Medium

   Placing ZCCHC10 upstream of NF-κB as a negative regulator explained how its loss promotes EMT, migration, and invasion in colorectal cancer, and revealed miR-410-3p as a post-transcriptional silencer of ZCCHC10.

   Evidence Dual-luciferase 3′UTR reporter assay, siRNA knockdown, NF-κB inhibitor (BAY 11-7082) rescue, wound healing and Transwell invasion assays

   PMID:33517196

   Open questions at the time

   • The molecular mechanism by which ZCCHC10 inhibits NF-κB activation is undefined (direct vs. indirect)
   • Findings come from a single laboratory without in vivo validation
   • Relationship between ZCCHC10's NF-κB suppression and its p53 stabilization function is unexplored
4. 2023 High

   Discovery that lncRNA SNHG1 epigenetically silences ZCCHC10 by recruiting DNMT1/DNMT3B to its promoter CpG island explained how ZCCHC10 is downregulated in cancer and linked this silencing to venetoclax resistance in AML via reduced p53 activity.

   Evidence ChIP for DNMT1/DNMT3B recruitment, bisulfite sequencing, SNHG1 motif-deletion mutagenesis, xenograft mouse model in AML cells

   PMID:37052262

   Open questions at the time

   • Whether SNHG1-mediated silencing of ZCCHC10 operates across cancer types beyond AML is unknown
   • The extent to which ZCCHC10 promoter methylation accounts for its downregulation relative to miR-410-3p post-transcriptional silencing has not been compared
   • Whether restoring ZCCHC10 expression alone is sufficient to overcome venetoclax resistance in patient-derived models is untested

• How ZCCHC10's zinc-finger CCHC domain contributes to its molecular functions — including p53 binding, PITX1 interaction, and NF-κB suppression — and whether these activities are coordinated or independent in vivo remains an open question.
• No structural or domain-mapping data exist for ZCCHC10's interactions with p53 or MDM2
• No unbiased interactome or proteomics study has been performed for ZCCHC10
• The physiological role of ZCCHC10 in normal (non-cancer) tissues is entirely uncharacterized